Brief: Gritstone Bio Presents 6-Month Neutralizing Antibody (NAB) Data From Two Phase 1 Studies Evaluating Self-Amplifying Mrna (Samrna) Against Sars-Cov-2 (Coral)
17/04/2023 12:05
April 17 (Reuters) - Gritstone bio Inc GRTS.O :
* GRITSTONE BIO PRESENTS 6-MONTH NEUTRALIZING ANTIBODY (NAB)
DATA
AT ECCMID 2023 FROM TWO PHASE 1 STUDIES EVALUATING
SELF-AMPLIFYING MRNA (SAMRNA) AGAINST SARS-COV-2 (CORAL)
* GRITSTONE BIO INC - DATA FURTHER SUPPORT FAVORABLE
TOLERABILITY
AND DISTINCTIVE IMMUNOGENICITY PROFILE OF SELF-AMPLIFYING MRNA
(SAMRNA)
Source text for Eikon: ID:nGNX8pFphV
Further company coverage: GRTS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gritstone bio
See all newsBrief: Gritstone Bio Inc On Dec 31 2024, Vassiliki “Celia” Economides Became Interim CEO As Well As CFO Of Co
Brief: Gritstone Bio Announces Strengthening Of Maturing Phase 2 PFS Data for GRANITE Study And Provides Business Update
U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma
U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma
U.S. STOCKS ON THE MOVE-PPG Industries, Travelers, ShiftPixy